Valuation: Roche Holding AG

Market Cap 291B 351B 309B 266B 496B 33,723B 501B 3,486B 1,353B 17,196B 1,320B 1,291B 55,737B P/E 2026 *
19.8x
P/E 2027 * 17.8x
Enterprise Value 302B 364B 320B 275B 515B 34,982B 519B 3,616B 1,403B 17,838B 1,369B 1,339B 57,818B EV / Sales 2026 *
4.81x
EV / Sales 2027 * 4.5x
Free-Float
88.78%
Yield 2026 *
2.75%
Yield 2027 * 2.82%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 352B
+2.68%+3.87%+58.22%+114.68% 1,026B
+0.56%+1.27%+53.29%+68.65% 649B
+0.02%+0.99%+19.10%+73.58% 468B
+0.06%+0.25%+37.03%+45.71% 352B
+1.16%+4.10%+21.99%+29.39% 271B
-0.24%+2.18%+10.14%+12.26% 256B
-0.01%+7.89%+41.57%+51.68% 220B
-1.11%+1.36%+30.85%+99.56% 188B
+0.30%-7.19%-32.43%-60.56% 170B
Average -0.06%+1.26%+26.64%+48.33% 399.9B
Weighted average by Cap. +0.02%+1.26%+37.30%+67.68%

Financials

2026 *2027 *
Net sales 62.66B 75.63B 66.47B 57.22B 107B 7,266B 108B 751B 291B 3,705B 284B 278B 12,009B 65.47B 79.03B 69.46B 59.79B 112B 7,593B 113B 785B 305B 3,872B 297B 291B 12,549B
Net income 14.51B 17.51B 15.39B 13.25B 24.76B 1,682B 24.97B 174B 67.48B 858B 65.83B 64.39B 2,780B 16.33B 19.71B 17.32B 14.91B 27.87B 1,894B 28.11B 196B 75.96B 966B 74.11B 72.49B 3,130B
Net Debt 10.86B 13.11B 11.52B 9.92B 18.54B 1,259B 18.7B 130B 50.52B 642B 49.28B 48.21B 2,081B 3.99B 4.82B 4.24B 3.65B 6.82B 463B 6.88B 47.88B 18.58B 236B 18.13B 17.73B 766B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA